ArticleFrontiers in immunology2026
UPLC-MS/MS-based metabolomics analysis identifies disease-associated metabolic signatures of B cells from patients with IgG4-RD.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin G4-related disease (IgG4-RD) is an autoimmune-mediated fibro-inflammatory disorder. Enhanced B-cell differentiation, along with its contribution to inflammatory and fibrotic pathological processes, represents a core mechanism in IgG4-RD. However, the metabolic characteristics of B cells in these patients have yet to be systematically investigated. Methods: Targeted metabolomic analysis was performed on sorted B cells from 32 IgG4-RD patients and 31 healthy controls using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Differential metabolites between the two groups were identified using the Mann-Whitney U test and orthogonal partial least squares-discriminant analysis (OPLS-DA). Metabolic pathway enrichment analysis of differentially expressed metabolites was conducted using the MetaboAnalyst 6.0 platform. In an independent validation cohort, flow cytometry was employed to detect B-cell subpopulations, lipid content, and the expression of stearoyl-CoA desaturase 1 (SCD1). Results: Significant differences in metabolite profiles were observed between B cells from IgG4-RD patients and healthy controls. Compared to healthy controls, 24 metabolites were significantly upregulated and 124 metabolites were significantly downregulated in B cells from IgG4-RD patients. A panel of 14 metabolites demonstrated optimal performance in distinguishing IgG4-RD B cells from control B cells (AUC = 0.934). The upregulated metabolites were primarily enriched in pathways such as glutathione metabolism and unsaturated fatty acid biosynthesis, whereas various amino acid metabolism pathways were significantly downregulated. Lipid content was significantly elevated in B cells of IgG4-RD patients compared to healthy controls, with plasmablasts/plasma cells exhibiting the highest lipid content and fatty acid synthase expression among all B-cell subsets. The glutamate/glutamine ratio was significantly elevated in B cells of the fibrotic subgroup compared to the inflammatory subgroup of IgG4-RD. Taurocholic acid (TCA) and dimethylglycine showed correlations with serum IgG4 and IgE levels, respectively. Conclusion: This study reveals distinct metabolic features of pathogenic B cells in IgG4-RD, proposing the hypothesis that metabolic dysregulation contributes to their pathogenic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.